Prithvi Sharma, MD
Cardiovascular Disease · Camarillo, CANPI 1265540470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novartis at 44.9% of the total. Reporting peaked in 2022 at $170 and has fallen 68.5% since, to $54 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 24 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$215
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$86
- Boston Scientific$47
- E.r. Squibb & Sons, L.L.C.$39
- Edwards Lifesciences$31
- Abbott$30
- plus $31 from 2 others
What the payments were for
- Food & beverage$479100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $215 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $86 |
| Boston Scientific | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Edwards Lifesciences | 1 | $31 |
| Abbott | 1 | $30 |
| Johnson & Johnson | 1 | $18 |
| AstraZeneca | 1 | $13 |
How this compares
$479 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $47,960 |
| Metoprolol Succinate | 70 | $1,423 |
| Levothyroxine Sodium | 27 | $1,289 |
| Atorvastatin Calcium | 100 | $1,074 |
| Valsartan | 11 | $882 |
| Digoxin | 23 | $806 |
| Losartan Potassium | 70 | $797 |
| Hydralazine Hcl | 23 | $514 |
| Atenolol | 13 | $420 |
| ClopidogrelClopidogrel Bisulfate | 14 | $363 |
| Simvastatin | 18 | $327 |
| Doxazosin Mesylate | 13 | $319 |
| Amiodarone Hcl | 13 | $270 |
| Metoprolol Tartrate | 16 | $255 |
| Warfarin Sodium | 25 | $221 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Camarillo
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.